Bio-Path Holdings, Inc., (OTCBB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Dr. Ana Maria Tari, PhD, MBA has been appointed Director, Preclinical Operations and Research. She will report to Peter Nielsen, President and Chief Executive Officer and be responsible for leading the Company’s evaluation and selection of new drug targets for licensing and development; design, source and direct preclinical in vitro and in vivo studies; and be the primary scientific liaison to the scientific community and clinical trial sites, including University of Texas M. D. Anderson Cancer Center.

Dr. Tari was a key member of the research team that performed the basic research and preclinical development of the liposomal delivery technology that Bio-Path has licensed from The University of Texas M. D. Anderson Cancer Center and is at the core of the Company’s research and development efforts. In particular, Dr. Tari was the lead researcher who developed the Company’s lead product candidate Liposomal Grb-2 (BP-100-1.01) that is currently in a Phase I clinical trial in blood cancers. Dr. Tari has authored or co-authored numerous articles in leading scientific journals, including several on the research done in Liposomal Grb-2. Previously, Dr. Tari has performed consulting work for the Company, being particularly instrumental in the transfer of licensed technology to the Company including manufacturing techniques, drug assays and testing methods.

Peter Nielsen, President and Chief Executive Officer of Bio-Path commented, “We are very fortunate to have Ana Tari join Bio-Path. Ana is a leader in the field of liposomal antisense therapeutics and will prove to be an invaluable resource as we develop and commercialize our proprietary neutral lipid delivery technology of which Ana was instrumental in developing. I look forward to working with Ana as we continue to advance our technology in our current clinical trial and her experience in the identification of new drug candidates and clinical trial design will be instrumental when we seek to expand into new drug targets.”

Dr. Tari holds a Bachelor of Science in chemistry and mathematics from Lincoln Memorial University, Harrogate, Tennessee and a PhD in biochemistry from the University of Tennessee in Knoxville, and an MBA from the University of Florida in Gainesville. Dr. Tari was a Postdoctoral Fellow in the department of clinical investigations at University of Texas M. D. Anderson Cancer Center. She then joined University of Texas M. D. Anderson Cancer Center as faculty from 1994 through 2009, holding positions as Assistant Professor and Associated Professor in the department of experimental therapeutics. Dr. Tari was also a faculty member of The University of Texas Graduate School of Biomedical Sciences. In 2009, Dr. Tari became an Associate Professor at the University of Florida Gainesville. In addition to her duties with Bio-Path, Dr. Tari will continue to work at the University of Florida.

Bio-Path is developing a neutral lipid-based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules), a delivery technology that forms microscopic-sized vehicles to safely deliver these drugs to their intended target cancer cells.

Bio-Path’s drug delivery technology involves microscopic-sized liposome particles that distribute nucleic acid drugs systemically and safely throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded (siRNA) and single stranded (antisense) nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. Bio-Path also anticipates developing liposome tumor targeting technology, representing next-generation enhancements to the Company’s core liposome delivery technology.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors, and its third candidate is a liposomal siRNA cancer drug that is in the final pre-clinical development stage. These product candidates and the delivery technology have been licensed from The University of Texas M. D. Anderson Cancer Center.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Bio-Path Holdings or at . Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at

Copyright Business Wire 2010

If you liked this article you might like

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves